Kamada Ltd Stock Price, News & Analysis

Kamada Ltd. reported Q1 2022 revenues of $28.1 million, a 13% year-over-year increase. The company reiterated its full-year revenue guidance of $125 million to $135 million, projecting a 20% to 30% growth compared to 2021. Gross margins improved to 40%, up from 36% in Q1 2021. Kamada generated $5.5 million in operating cash flows, raising total available cash to $22 million. The company noted a net loss of $1.8 million in the quarter, mainly impacted by increased operating expenses due to R&D and sales efforts.

Kamada Ltd. (NASDAQ: KMDA) provided an update on its pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin (AAT) therapy, targeting Alpha-1 Antitrypsin Deficiency (AATD). The trial is expanding to new sites in Belgium, Finland, Sweden, the UK, Ireland, and the Netherlands, with patient enrollment underway. The Independent Data Safety Monitoring Board (DSMB) has recommended continuing the trial without modifications, reporting no serious adverse events. The trial aims to enroll up to 250 patients, assessing lung function and other parameters over two years.

Kamada Ltd. (NASDAQ: KMDA) will announce its financial results for Q1 2022 on May 17, before U.S. markets open. The company, known for its specialty plasma-derived therapeutics, will conduct a conference call at 8:30 AM ET on the same day to discuss the results. Interested parties can join the call or access it via a live webcast. Kamada’s portfolio includes FDA-approved products like GLASSIA® and KEDRAB®, along with recently acquired plasma-derived hyperimmune products. The company aims to leverage its development pipeline and manufacturing capabilities to drive growth.

Kamada Ltd. (NASDAQ: KMDA) reported a transformational year in 2021, completing the transition of Glassia® manufacturing to Takeda and acquiring four FDA-approved immunoglobulins. The company anticipates 2022 revenues between $125M and $135M, reflecting 20%-30% growth, with EBITDA margins projected at 12%-15%. Kamada has entered the U.S. plasma collection market and plans to expand its product portfolio. Key products include Cytogam® and KedRAB®, with expected sales growth. The company is optimistic about its clinical pipeline, particularly its inhaled AAT treatment for AAT deficiency, currently in a pivotal Phase 3 trial.

Kamada Ltd. (NASDAQ: KMDA) reported total revenues of $103.6 million for fiscal year 2021 and $31.5 million for Q4 2021. For fiscal year 2022, revenues are projected to be between $125 million and $135 million, reflecting a 20% to 30% increase over 2021. EBITDA margins are expected to be 12% to 15%. The company is integrating newly acquired FDA-approved products and expanding U.S. plasma collection operations. A key highlight includes the initiation of GLASSIA royalty payments from Takeda in Q2 2022.

Kamada Ltd. has announced the appointments of Jon R. Knight as Vice President of U.S. Commercial Operations and Jonathan Ward as Director of Facilities and Construction. These changes aim to enhance U.S. operations and expand plasma collection capabilities, especially related to the company’s recently acquired portfolio of four FDA-approved plasma-derived hyperimmune products. Knight's experience in plasma product commercialization and Ward's expertise in facility management are expected to drive sales growth and new center openings, respectively.

Kamada Ltd. (NASDAQ: KMDA) will release its financial results for Q4 and FY 2021 on March 15, 2022. A conference call for investors will follow at 8:30 AM ET, where management will discuss results and answer questions. Kamada is a leader in the plasma-derived biopharmaceutical industry, focusing on expanding its product portfolio, including FDA-approved treatments like GLASSIA® and CYTOGAM®. The company aims to drive growth through robust development and manufacturing capabilities.

Kamada has acquired a portfolio of four FDA-approved plasma-derived hyperimmune products from Saol Therapeutics for $95 million upfront and up to $50 million in sales milestones through 2034. The global revenue from the products is estimated between $40 million to $45 million, with 75% of sales from the U.S. and 20% from Canada. This acquisition positions Kamada to become a global leader in plasma-derived therapies, enhancing its commercial capabilities in the U.S. market while gaining access to eight additional international markets, mainly in the MENA region.

Kamada Ltd. (NASDAQ: KMDA) reported Q3 2021 revenues of $23.0 million, down from $35.3 million in Q3 2020. The company acquired a portfolio of four FDA-approved plasma-derived products from Saol Therapeutics, expected to generate annual revenues of $40 million to $45 million. The transition of GLASSIA® manufacturing to Takeda is complete, moving to a royalty phase in 2022. The company aims to expand its plasma collection capabilities in the U.S. while advancing the Phase 3 InnovAATe trial for Inhaled AAT. As of September 30, 2021, cash and equivalents stood at $99.8 million.